24. A host cell comprising the expression vector as defined in claim 23.

25. The host cell according to claim 24, which is an *E. coli* cell.

26. A pharmaceutical composition comprising as an active ingredient the fusion protein as defined in any one of claims 1 to 19, in combination with a pharmaceutically acceptable carrier.

27. The pharmaceutical composition according to claim 26 in a form for parenteral administration.

28. The fusion protein as defined in any one of claims 1 to 19 for use in the treatment of neoplastic diseases in mammals, including humans.

~~29. A method of treating cancer diseases in mammal, including human, which comprises administration to a subject in a need thereof an anti-neoplastic effective amount of the fusion protein as defined in claims 1 to 19, or the pharmaceutical composition as defined in claims 26 or 27.~~

~~30. Peptide selected from the group consisting of a fusion peptide comprising an EGF inhibitor and synthetic lytic peptide of SEQ. No. 56 and a fusion variant of PDGF antagonist and synthetic lytic peptide of SEQ. No. 125.~~